vs
PHIBRO ANIMAL HEALTH CORP（PAHC）とEPLUS INC（PLUS）の財務データ比較。上の社名をクリックして会社を切り替えられます
EPLUS INCの直近四半期売上が大きい（$614.8M vs $373.9M、PHIBRO ANIMAL HEALTH CORPの約1.6倍）。PHIBRO ANIMAL HEALTH CORPの純利益率が高く（7.3% vs 5.7%、差は1.6%）。PHIBRO ANIMAL HEALTH CORPの前年同期比売上増加率が高い（20.9% vs 20.3%）。過去8四半期でPHIBRO ANIMAL HEALTH CORPの売上複合成長率が高い（19.2% vs 2.3%）
ファイブローアニマルヘルスコーポレーションは米国の動物健康・ミネラル栄養企業で、抗菌剤、抗コクシジウム剤、駆虫薬のほか、家畜用栄養補給剤、ワクチンなどを製品ラインナップに持っています。ミネラル栄養、機能材料、動物健康の3事業セグメントを中心に収益を上げ、米国、中南米、カナダ、欧州、中東、アフリカ、アジア太平洋地域で事業を展開しています。
ePlus Inc.は米国発のコンサルティング型テクノロジーソリューションプロバイダーで、サイバーセキュリティ、クラウド、ネットワーク、コラボレーション、人工知能などの先進技術分野にわたり、5000社以上の顧客にソリューション、アドバイザリー、マネージドサービスを提供しています。
PAHC vs PLUS — 直接比較
損益計算書 — Q2 FY2026 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $373.9M | $614.8M |
| 純利益 | $27.5M | $35.1M |
| 粗利率 | 35.5% | 25.8% |
| 営業利益率 | 13.5% | 7.1% |
| 純利益率 | 7.3% | 5.7% |
| 売上前年比 | 20.9% | 20.3% |
| 純利益前年比 | 762.1% | 45.2% |
| EPS（希薄化後） | $0.67 | $1.33 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $373.9M | $614.8M | ||
| Q3 25 | $363.9M | $608.8M | ||
| Q2 25 | $378.7M | $637.3M | ||
| Q1 25 | $347.8M | — | ||
| Q4 24 | $309.3M | $493.2M | ||
| Q3 24 | $260.4M | $493.4M | ||
| Q2 24 | $273.2M | $535.7M | ||
| Q1 24 | $263.2M | — |
| Q4 25 | $27.5M | $35.1M | ||
| Q3 25 | $26.5M | $34.9M | ||
| Q2 25 | $17.2M | $37.7M | ||
| Q1 25 | $20.9M | — | ||
| Q4 24 | $3.2M | $24.1M | ||
| Q3 24 | $7.0M | $31.3M | ||
| Q2 24 | $752.0K | $27.3M | ||
| Q1 24 | $8.4M | — |
| Q4 25 | 35.5% | 25.8% | ||
| Q3 25 | 32.9% | 26.6% | ||
| Q2 25 | 29.0% | 23.3% | ||
| Q1 25 | 30.1% | — | ||
| Q4 24 | 32.9% | 25.4% | ||
| Q3 24 | 32.1% | 25.8% | ||
| Q2 24 | 31.9% | 23.7% | ||
| Q1 24 | 30.2% | — |
| Q4 25 | 13.5% | 7.1% | ||
| Q3 25 | 14.1% | 8.0% | ||
| Q2 25 | 8.9% | 5.7% | ||
| Q1 25 | 9.6% | — | ||
| Q4 24 | 8.3% | 3.3% | ||
| Q3 24 | 6.8% | 5.5% | ||
| Q2 24 | 6.7% | 5.9% | ||
| Q1 24 | 7.6% | — |
| Q4 25 | 7.3% | 5.7% | ||
| Q3 25 | 7.3% | 5.7% | ||
| Q2 25 | 4.5% | 5.9% | ||
| Q1 25 | 6.0% | — | ||
| Q4 24 | 1.0% | 4.9% | ||
| Q3 24 | 2.7% | 6.3% | ||
| Q2 24 | 0.3% | 5.1% | ||
| Q1 24 | 3.2% | — |
| Q4 25 | $0.67 | $1.33 | ||
| Q3 25 | $0.65 | $1.32 | ||
| Q2 25 | $0.43 | $1.43 | ||
| Q1 25 | $0.51 | — | ||
| Q4 24 | $0.08 | $0.91 | ||
| Q3 24 | $0.17 | $1.17 | ||
| Q2 24 | $0.02 | $1.02 | ||
| Q1 24 | $0.21 | — |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $74.5M | $326.3M |
| 総負債低いほど良い | $624.2M | — |
| 株主資本純資産 | $332.4M | $1.1B |
| 総資産 | $1.4B | $1.8B |
| 負債/資本比率低いほどレバレッジが低い | 1.88× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $74.5M | $326.3M | ||
| Q3 25 | $85.3M | $402.2M | ||
| Q2 25 | $77.0M | $480.2M | ||
| Q1 25 | $70.4M | — | ||
| Q4 24 | $67.1M | $253.1M | ||
| Q3 24 | $89.8M | $187.5M | ||
| Q2 24 | $114.6M | $349.9M | ||
| Q1 24 | $98.7M | — |
| Q4 25 | $624.2M | — | ||
| Q3 25 | $628.0M | — | ||
| Q2 25 | $631.7M | — | ||
| Q1 25 | $635.4M | — | ||
| Q4 24 | $639.1M | — | ||
| Q3 24 | $295.2M | — | ||
| Q2 24 | $312.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $332.4M | $1.1B | ||
| Q3 25 | $311.7M | $1.0B | ||
| Q2 25 | $285.7M | $1.0B | ||
| Q1 25 | $266.0M | — | ||
| Q4 24 | $246.8M | $962.3M | ||
| Q3 24 | $258.5M | $947.0M | ||
| Q2 24 | $256.6M | $921.9M | ||
| Q1 24 | $270.1M | — |
| Q4 25 | $1.4B | $1.8B | ||
| Q3 25 | $1.4B | $1.8B | ||
| Q2 25 | $1.4B | $1.8B | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | $1.8B | ||
| Q3 24 | $966.3M | $1.7B | ||
| Q2 24 | $982.2M | $1.7B | ||
| Q1 24 | $979.0M | — |
| Q4 25 | 1.88× | — | ||
| Q3 25 | 2.01× | — | ||
| Q2 25 | 2.21× | — | ||
| Q1 25 | 2.39× | — | ||
| Q4 24 | 2.59× | — | ||
| Q3 24 | 1.14× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $19.4M | $-87.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $8.3M | — |
| FCFマージンFCF / 売上 | 2.2% | — |
| 設備投資強度設備投資 / 売上 | 3.0% | — |
| キャッシュ転換率営業CF / 純利益 | 0.70× | -2.49× |
| 直近12ヶ月FCF直近4四半期 | $47.3M | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $19.4M | $-87.4M | ||
| Q3 25 | $9.3M | $-34.8M | ||
| Q2 25 | $21.3M | $-99.0M | ||
| Q1 25 | $43.2M | — | ||
| Q4 24 | $3.1M | $65.7M | ||
| Q3 24 | $12.6M | $-21.6M | ||
| Q2 24 | $28.4M | $97.1M | ||
| Q1 24 | $11.4M | — |
| Q4 25 | $8.3M | — | ||
| Q3 25 | $-4.5M | — | ||
| Q2 25 | $8.1M | — | ||
| Q1 25 | $35.4M | — | ||
| Q4 24 | $-4.7M | — | ||
| Q3 24 | $3.0M | — | ||
| Q2 24 | $15.4M | — | ||
| Q1 24 | $1.7M | — |
| Q4 25 | 2.2% | — | ||
| Q3 25 | -1.2% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 10.2% | — | ||
| Q4 24 | -1.5% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 5.6% | — | ||
| Q1 24 | 0.6% | — |
| Q4 25 | 3.0% | — | ||
| Q3 25 | 3.8% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 2.5% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 4.8% | — | ||
| Q1 24 | 3.7% | — |
| Q4 25 | 0.70× | -2.49× | ||
| Q3 25 | 0.35× | -1.00× | ||
| Q2 25 | 1.24× | -2.63× | ||
| Q1 25 | 2.07× | — | ||
| Q4 24 | 0.97× | 2.72× | ||
| Q3 24 | 1.81× | -0.69× | ||
| Q2 24 | 37.80× | 3.55× | ||
| Q1 24 | 1.36× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
PLUS
| All Others Customer End Market | $107.0M | 17% |
| Technology Customer End Market | $89.4M | 15% |
| Health Care Customer End Market | $81.5M | 13% |
| Financial Services Customer End Market | $66.1M | 11% |
| Professional Services Reporting Unit | $64.1M | 10% |
| Security | $61.1M | 10% |
| State And Local Government And Educational Institutions | $59.9M | 10% |
| Managed Services Reporting Unit | $48.8M | 8% |
| Other Product | $21.1M | 3% |
| Collaboration | $13.4M | 2% |
